Glenmark settles up with Merck for Zetia

12 May 2010 Evaluate

Drug-maker Glenmark is set to benefit from the settlement of its patent litigation with Merck on ezetimibe, the cholesterol-modifying drug sold by the latter as Zetia. Zetia is a blockbuster product, with its sales in the US estimated at $1.4 billion.

 

The settlement gives Glenmark a four-and-a-half-month period of exclusive sales that gets shared with Par Pharmaceutical, following a deal on the same drug earlier this month. The settlement with Merck ends the lawsuit involving a challenge by Glenmark – as it sought to launch a generic version of Zetia before the April 2017 expiration of the patent exclusivity on the drug.

 

The agreement will now allow Glenmark to launch its product in the US on December 12, 2016, or earlier under certain circumstances, ahead of the April 25, 2017, expiration of Merck's patent exclusivity for Zetia.

 

Glenmark looks set to get about $150 million when generic Zetia hits the market in 2016, despite the licensing and supply agreement with Par Pharma. Under the existing agreement, Par had paid Glenmark for exclusive rights to market, sell and distribute ezetimibe in the US. The companies will share profits from the sales of the product.

crackcrack

Glenmark Pharma Share Price

1178.00 17.25 (1.49%)
03-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1453.25
Dr. Reddys Lab 5792.95
Cipla 1459.85
Zydus Lifesciences 1032.25
Lupin 1583.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.